Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glucagon Phenotype and CNS Response
NCT03061227Completed
- Sponsor
- University Hospital Tübingen
- Start
- Feb 2017
- Primary completion
- Jan 2019
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, double-blind trial of glucagon in metabolic syndrome and type 2 diabetes mellitus (T2DM), sponsored by University Hospital Tübingen. Primary endpoint: Brain activity at 120 months. Started Feb 2017; status: completed.
02
Drugs
glucagon
03
Conditions
metabolic syndrometype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03061227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03061227.